Italfarmaco SpA and Iktos SA have entered into a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.

Alivexis Inc. has entered into a research collaboration agreement with Astellas Pharma Inc. to identify small-molecule compounds for a new drug target selected by Astellas.

In what represents its first patenting Demon Curonix BV is seeking protection for a system for providing microvesicles to be used in combination with focused ultrasound for drug delivery to the brain.

A collaborating team of researchers from Northwestern University and Rice University continue to build intellectual property for an implanted biohybrid (bioelectronic/engineered cell) device that has been likened to an implantable pharmacy on a chip that never runs out.

The world’s largest and most comprehensive repository of somatic mutations found in cancer is celebrating its 20th birthday by adding 307,000 new genomic variants to its 24 million-strong database. With somatic mutations being the main drivers of tumor development, the Catalogue of Somatic Mutations in Cancer (COSMIC) is firmly established as a source of potential drug targets, for the discovery and validation of biomarkers associated with prognosis, treatment response and patient outcomes, and as a resource for characterizing the mutational landscape of individual tumors.

Cancervax Inc. has announced that its University of California, Los Angeles (UCLA) research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNPs) using click chemistry, for targeting cancer cells.

Totus Medicines Inc. has entered into a multi-target research collaboration with Eli Lilly & Co. to discover small-molecule drug candidates against undisclosed targets in different therapeutic areas.

The success of a vaccine, a gene editing design for an untreated disease, or achieving cell engraftment after several attempts, comes from years of accumulated basic science studies, thousands of experiments, and clinical trials. Innumerable steps precede hits in gene and cell therapies before a first-time revelation, and most of them are failures at the time. At the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Baltimore last week, several groups of scientists presented achievements that years ago looked impossible.

Neosphere Biotechnologies GmbH has entered into a collaboration with Kymera Therapeutics Inc. that seeks to unlock undrugged or poorly drugged disease-causing protein targets that can be addressed by targeted protein degradation.